semaglutide & tirzepatide and key differences, weight loss results (2026) Tirzepatide vs. Semaglutide for Weight

Vyvanse is a central nervous system stimulant, and its active ingredient is lisdexamfetamine dimesylate

According to its recently released findings, Phase 1 clinical studies showed that obese participants achieved an average 6.9 percent weight loss over a four-week period, with a maximum weight cut of 11.9 percent

FAIR Health report examined data from 51 billion commercial healthcare claim records, the US largest such database, to examine trends in obesity and GLP-1 drug prescriptions among adult patients during the period 2019-2024

Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases

GHK-Cu and related copper peptides upregulate vascular endothelial growth factor (VEGF), which promotes the formation of new blood vessels

In vivo measurement of energy substrate contribution to cold-induced brown adipose tissue thermogenesis